Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical data trend for Lyka Labs's OCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:LYKALABS vs VRTX, REGN, RVMD: OCF Margin % Comparison
For the Biotechnology subindustry, Lyka Labs's OCF Margin %, along with its competitors' market caps and OCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lyka Labs OCF Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Lyka Labs's OCF Margin % distribution charts can be found below:
* The bar in red indicates where Lyka Labs's OCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lyka Labs (NSE:LYKALABS) has a OCF Margin % of 0.00% as of Mar. 2026. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Lyka Labs and its competitors. Over the past decade, Lyka Labs' OCF Margin % has ranged from 1.37 to 43.17. According to the industry distribution chart, Lyka Labs ranks #269 out of 953 companies in the Biotechnology industry, placing it in the top 28.2%.
Is Lyka Labs' OCF Margin % too high?
Lyka Labs' current OCF Margin % is 0.00%. Over the past 10 years, this metric has ranged from a low of 1.37 to a high of 43.17. Based on the distribution chart, Lyka Labs ranks #269 out of 953 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Lyka Labs has a GF Score™ of 55/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Lyka Labs' OCF Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Lyka Labs ranks #269 out of 953 companies for OCF Margin %. This puts Lyka Labs in the upper half of its industry. Historically, Lyka Labs' own OCF Margin % has ranged from 1.37 to 43.17 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Biotechnology company?
A good OCF Margin % depends on the Biotechnology industry context. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Lyka Labs and its competitors. Lyka Labs's current OCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lyka Labs stock overvalued right now?
Based on GuruFocus' analysis, Lyka Labs (NSE:LYKALABS) is currently considered Significantly Undervalued. The stock's GF Value™ is ₹128.29, compared to a current price of ₹66.66 — trading 48% below its estimated fair value. The current OCF Margin % is 0.00%. Lyka Labs' overall GF Score™ is 55/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Lyka Labs (NSE:LYKALABS), the current OCF Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Lyka Labs (NSE:LYKALABS) Overvalued in 2026?
Based on GuruFocus' analysis, Lyka Labs stock appears to be undervalued.
The current stock price of ₹66.66 is trading 48% below its estimated GF Value™ of ₹128.29.
GuruFocus considers Lyka Labs to be Significantly Undervalued.
Key valuation signals for NSE:LYKALABS:
OCF Margin %: 0.00%
GF Value™: ₹128.29 vs. price of ₹66.66 (48% below fair value)
No single metric tells the full story. See the NSE:LYKALABS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Lyka Labs Ltd is an Indian biotechnology company. It mainly engages in the development of specialized formulations. The Company is engaged in only one segment which is pharmaceuticals. The Company has a presence in Domestic as well as International markets. The commercialized formulations of the company consist of hair care, anti-aging, acne management, skin lightening, face washes, sunscreens, facial scrubs, and others. It has developed a varied drug delivery system for topical steroids, painkillers, anti-fungal, and other emollients as well as liquid injectables, lyophilized injectables in the anti-bacterial, antifungal segment. The company also manufactures proton pump inhibitors, antibiotics, antifungals, steroids, etc. The majority of the company's revenue comes from India.
55GF Score
Get the complete analysis for NSE:LYKALABS
OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:LYKALABS has been successfully added to your 
